# BioAge Labs, Inc.: overview

BIOA · Nasdaq · CIK 1709941 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bioa.md) · [Financials](/companies/bioa/financials.md) · [Filings](/companies/bioa/filings.md) · [Insiders](/companies/bioa/insiders.md)

Latest reported revenue: [$2.5m](/filings/0001193125-26-335407.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-335407).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001193125-25-270012.md) | [0.0 d](/filings/0001193125-26-120873.md) | [1.5](/filings/0001193125-26-213466.md) | [2.4](/filings/0001193125-26-335407.md) | [2.1](/filings/0001193125-25-270012.md) | [3.1 d](/filings/0001193125-26-120873.md) | [2.8](/filings/0001193125-26-213466.md) | [2.5](/filings/0001193125-26-335407.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | [(1133.4%)](/filings/0001193125-26-213466.md) | [(1027.0%)](/filings/0001193125-26-335407.md) | [(1126.6%)](/filings/0001193125-25-270012.md) | [(923.4%) d](/filings/0001193125-26-120873.md) | [(915.4%)](/filings/0001193125-26-213466.md) | [(1196.8%)](/filings/0001193125-26-335407.md) |
| Net margin | % | not reported | not reported | [(891.0%)](/filings/0001193125-26-335407.md) | [(894.0%)](/filings/0001193125-26-335407.md) | [(982.0%)](/filings/0001193125-25-270012.md) | [(842.9%) d](/filings/0001193125-26-120873.md) | [(802.8%)](/filings/0001193125-26-335407.md) | [(1064.7%)](/filings/0001193125-26-335407.md) |
| Diluted EPS | $ per share | [(6.70)](/filings/0001193125-25-270012.md) | not reported | [(0.36)](/filings/0001193125-26-213466.md) | [(0.60)](/filings/0001193125-26-335407.md) | [(0.56)](/filings/0001193125-25-270012.md) | not reported | [(0.52)](/filings/0001193125-26-213466.md) | [(0.58)](/filings/0001193125-26-335407.md) |
| Free cash flow | $m | [(15.2) d](/filings/0001193125-25-270012.md) | [(5.2) d](/filings/0001193125-26-120873.md) | [(17.8)](/filings/0001193125-26-213466.md) | [(20.1) d](/filings/0001193125-26-335407.md) | [(16.1) d](/filings/0001193125-25-270012.md) | [(28.4) d](/filings/0001193125-26-120873.md) | [(24.1)](/filings/0001193125-26-213466.md) | [(19.6) d](/filings/0001193125-26-335407.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: |
| Revenue | $m | not reported | [0.0](/filings/0001193125-26-120873.md) | [9.0](/filings/0001193125-26-120873.md) |
| Gross margin | % | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | [(1031.5%)](/filings/0001193125-26-120873.md) |
| Net margin | % | not reported | not reported | [(896.1%)](/filings/0001193125-26-120873.md) |
| Diluted EPS | $ per share | [(38.17)](/filings/0000950170-25-042759.md) | [(6.63)](/filings/0001193125-26-120873.md) | [(2.24)](/filings/0001193125-26-120873.md) |
| Free cash flow | $m | [(37.5)](/filings/0000950170-25-042759.md) | [(51.9)](/filings/0001193125-26-120873.md) | [(82.3)](/filings/0001193125-26-120873.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bioa/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [a16z Capital Management, L.L.C.](/funds/1540358.md) | 2026-06-30 | $79.2m | 3,233,170 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $69.8m | 2,849,077 |  | Added +581,321 |
| [Cormorant Asset Management, LP](/funds/1583977.md) | 2026-06-30 | $58.6m | 2,390,605 |  | Reduced −500,000 |
| [Sofinnova Investments, Inc.](/funds/1631134.md) | 2026-06-30 | $56.2m | 2,293,788 |  | Unchanged |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $52.6m | 2,144,633 |  | Not compared |
| [Octagon Capital Advisors LP](/funds/1839435.md) | 2026-06-30 | $42.8m | 1,748,000 |  | Unchanged |
| [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $41.0m | 1,671,648 |  | Added +21,000 |
| [MPM BIOIMPACT LLC](/funds/1687078.md) | 2026-06-30 | $40.9m | 1,667,661 |  | New +1,667,661 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $37.8m | 1,544,214 |  | Added +189,308 |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $36.6m | 2,094,270 |  | Not compared |

## Recent filings

[All 154 filings](/companies/bioa/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-02 | 20:15 ET | [8-K](/filings/0001193125-26-412300.md) | 8.01 Other events | 0001193125-26-412300 |
| 2026-08-05 | 21:00 ET | [10-Q](/filings/0001193125-26-335407.md) | Quarterly report, period 2026-06-30 | 0001193125-26-335407 |
| 2026-08-05 | 20:55 ET | [8-K](/filings/0001193125-26-335368.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-335368 |
| 2026-06-12 | 12:00 ET | [8-K](/filings/0001193125-26-268518.md) | 5.07 Shareholder vote results | 0001193125-26-268518 |
| 2026-05-08 | 13:10 ET | [8-K](/filings/0001193125-26-213472.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-213472 |
| 2026-05-08 | 13:05 ET | [10-Q](/filings/0001193125-26-213466.md) | Quarterly report, period 2026-03-31 | 0001193125-26-213466 |
| 2026-04-21 | 20:05 ET | [DEF 14A](/filings/0001193125-26-166738.md) | Proxy statement, period 2026-06-10 | 0001193125-26-166738 |
| 2026-03-24 | 13:15 ET | [10-K](/filings/0001193125-26-120873.md) | Annual report, period 2025-12-31 | 0001193125-26-120873 |
| 2026-03-24 | 13:10 ET | [8-K](/filings/0001193125-26-120864.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-120864 |
| 2026-01-22 | 21:34 ET | [8-K](/filings/0001193125-26-019536.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-019536 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-120873.md), filed Mar 24, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/ba81eafa-3abc-47f7-8859-af055bda7934)

## About the filer

- CIK: 1709941
- Tickers: BIOA
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.